Designing a New Peptide-Centric TCR Mimic for Cancer Therapy
Author Information
Author(s): Karsten D. Householder, Xinyu Xiang, Kevin M. Jude, Arthur Deng, Matthias Obenaus, Steven C. Wilson, Xiaojing Chen, Nan Wang, K. Christopher Garcia
Primary Institution: Stanford University School of Medicine
Hypothesis
Can a de novo α-helical TCR mimic be designed to specifically target tumor antigens with high affinity?
Conclusion
The study successfully designed a peptide-specific TCR mimic that shows high on-target specificity and potential for reduced off-target reactivity.
Supporting Evidence
- The TCR mimic showed a dissociation constant of 9.5 nM for the NY-ESO-1 peptide.
- Two out of five designs were specifically stained by the NY-ESO-1 tetramer but not by the MART-1 tetramer.
- The crystal structure revealed a TCR-like docking mode with a focus on peptide side chains.
- An in silico screen predicted off-target peptides with high accuracy.
- The TCR mimic maintained a wide therapeutic window as a T cell engager.
Takeaway
Researchers created a new type of protein that can help the immune system find and attack cancer cells more effectively.
Methodology
The study used computational design, high-throughput screening, and structural validation to create and test the TCR mimic.
Potential Biases
Potential for cross-reactivity due to the nature of TCR mimics.
Limitations
Further optimization and off-target screening are needed to confirm clinical applicability.
Statistical Information
P-Value
9.5 nM
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website